Mobic Generic Competition Possible In Early 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer Ingelheim brand rings up $293 mil. in first quarter sales as biggest beneficiary from COX-2 safety issues. Mobic loses exclusivity April 13, although generics are unlikely to enter the market for at least nine months.